PharmaTher Holdings Ltd. (PHRM.CN) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-87.3%

CA$0.01

vs CA$0.06 price

Levered DCF

CA$0.01

After debt service

Piotroski score

0 / 9

Weak

Altman Z-score

-14.58

Distress zone

Rating

D+

Overall 1 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
P/E	-8.96×	-12.21×	-5.67×	-1.51×	-3.04×	6.78×	-716.67×
P/B	8.91×	16.46×	7.55×	1.79×	1.03×	3.24×	39.34×
P/S	0×	0×	0×	0×	0×	0×	0×
EV / EBITDA	-5.64×	-9.92×	-5.1×	-0.95×	-0.76×	-6.3×	0×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	1.83×	3.11×	9.25×	7.07×	36.82×	33.83×	36.33×
Debt / equity	0×	0×	0×	0×	0×	0×	0×
Interest coverage	0×	0×	0×	0×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Return on equity	-99.6%	-156.8%	-133.3%	-118.4%	-33.9%	47.7%	-6.3%
Return on invested capital	-138.0%	-156.5%	-128.2%	-73.1%	-32.8%	-45.0%	-6.2%
Return on assets	-54.4%	-113.9%	-120.3%	-101.7%	-33.0%	44.8%	-6.1%
Free cash flow yield	-8.9%	-7.6%	-20.0%	-33.4%	-28.9%	5.1%	-0.0%
Earnings yield	-11.2%	-9.5%	-17.7%	-66.2%	-33.0%	14.7%	-0.2%
Enterprise value	CA$4.8M	CA$15.1M	CA$15.5M	CA$3.8M	CA$3M	CA$15.3M	CA$14.5M
Net debt / EBITDA	0.81×	0.61×	0.7×	1.5×	2.31×	1.14×	0×
Cash conversion cycle (days)	0	0	-125,321	-226,193	-65,831	-89,757	0